BML, INC. is mainly engaged in the clinical testing as well as related business. The Testing segment engages in the commissioned work of clinical testing. The Medical Information Systems segment is engaged in the manufacturing and sales of system equipment for medical institutions, as well as provision of medical information service.

Employees

4,558

Sector

Healthcare Facilities & Services

Calendar

Feb. 05 - Q3 2025 Earnings Release (Projected)

More about the company

Quotes

Date	Price	Change	Volume
25-12-05	3,835.00 ¥	+0.52%	66,600
25-12-04	3,815.00 ¥	+0.13%	38,800
25-12-03	3,810.00 ¥	+0.79%	73,500
25-12-02	3,780.00 ¥	-0.40%	56,000
25-12-01	3,795.00 ¥	-0.91%	34,200

Delayed Quote Japan Exchange, December 05, 2025 at 01:30 am EST

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

3,835.00JPY

Average target price

4,200.00JPY

Spread / Average Target

+9.52%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Japan Exchange Other stock markets 01:30:00 2025-12-05 am EST			5-day change	1st Jan Change
3,835.00 ^JPY	+0.52%		+0.79%	+31.97%

Nov. 07	BML, Inc. Announces Dividend for the Second Quarter End of Fiscal Year 2025, Payable on December 2, 2025	CI
Aug. 12	BML, Inc.'s Equity Buyback announced on August 8, 2025, has closed with 1,545,000 shares, representing 3.96% for ¥5,376.6 million.	CI

Capitalization	144B 925M 795M 745M 694M 1.28B 83.24B 1.39B 8.71B 3.36B 39.31B 3.47B 3.4B	P/E ratio 2026 *	22.4x	P/E ratio 2027 *	18.7x
Enterprise value	144B 925M 795M 745M 694M 1.28B 83.24B 1.39B 8.71B 3.36B 39.31B 3.47B 3.4B	EV / Sales 2026 *	0.97x	EV / Sales 2027 *	0.94x
Free-Float	54.99%	Yield 2026 *	3.13%	Yield 2027 *	3.39%

Nov. 07	BML, Inc. Announces Dividend for the Second Quarter End of Fiscal Year 2025, Payable on December 2, 2025	CI
Aug. 12	BML, Inc.'s Equity Buyback announced on August 8, 2025, has closed with 1,545,000 shares, representing 3.96% for ¥5,376.6 million.	CI
Aug. 12	Tranche Update on BML, Inc.'s Equity Buyback Plan announced on August 8, 2025.	CI
Aug. 08	BML, Inc. announces an Equity Buyback for 1,700,000 shares, representing 4.36% for ¥5,916 million.	CI
Aug. 07	BML, Inc. authorizes a Buyback Plan.	CI
Jul. 01	Supreme Court Upholds Fine Against Betsson Subsidiary BML	FW
May. 09	Bml, Inc. Announces Commemorative Dividend for Year End of Fiscal Year Ended March 31, 2025, Payable on June 30, 2025	CI
May. 09	Bml, Inc. Announces Dividend for Year End of Fiscal Year Ended March 31, 2025, Payable on June 30, 2025; Provides Dividend Guidance for Second Quarter End and Year End of Fiscal Year Ending March 31, 2026	CI
May. 09	Bml, Inc. Provides Earnings Guidance for Fiscal Year Ending March 31, 2026 (April 1, 2025 - March 31, 2026)	CI
May. 09	BML, Inc. Announces Board and Committee Changes	CI
Mar. 25	Lefroy Exploration Limited Receives All Drill Assay Results from its Resource Infill and Extensional Drilling Program at the Lucky Strike Gold Project	CI
24-05-14	Boab Metals Completes AU$1.7 Million Placement, Opens AU$3.3 Million Entitlement Offer	MT
24-05-06	Auric Mining Processes 30,300 Metric Tonnes from Jeffreys Find Gold Mine; Shares Up 6%	MT

23-08-09	BML : Consolidated Earnings Report for the First Quarter of Fiscal 2023	PU
23-02-09	BML : Consolidated Earnings Report for the Third Quarter of Fiscal 2022	PU
22-08-09	BML : Consolidated Earnings Report for the First Quarter of Fiscal 2022	PU
22-06-06	BML : Notice of The 67th Annual General Meeting of Shareholders	PU
22-05-12	BML : Financial Results Presentation for Fiscal 2021	PU

BML, Inc. Stock

Equities

4694

JP3799700004

Healthcare Facilities & Services

Valuation: BML, Inc.

Chart: BML, Inc.

Latest news: BML, Inc.

Press Releases: BML, Inc.

News in other languages: BML, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: BML, Inc.

ETFs: BML, Inc.

Medical & Diagnostic Laboratories

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Quarterly revenue - Rate of surprise

24-05-10	Diversificatie en kansen: de Japanse markt in de schijnwerpers
24-05-09	Diversificazione e opportunità: il mercato giapponese sotto i riflettori
24-05-08	Diversifikation und Chancen: Der japanische Markt im Rampenlicht
24-05-08	Diversification et opportunités : Le marché japonais à l’honneur
23-06-28	MORNING BRIEFING - USA/Asien

1 day	+0.52%
1 week	+0.79%
Current month	+0.13%
1 month	+5.94%
3 months	+4.35%
6 months	+27.83%
Current year	+31.97%

1 week	3,770	3,855
1 month	3,580	3,865
Current year	2,663	3,865
1 year	2,663	3,865
3 years	2,592	3,865
5 years	2,592	4,985
10 years	1,562.5	4,985

Manager	Title	Age	Since
Kensuke Kondo PSD	President	59	2013-12-31
Nobuki Arai ADM	Chief Administrative Officer	65	2020-03-31
Yuji Yamashita PRN	Corporate Officer/Principal	60	2020-03-31

Director	Title	Age	Since
Kensuke Kondo BRD	Director/Board Member	59	2006-05-31
Nobuki Arai BRD	Director/Board Member	65	2009-05-31
Masato Denawa BRD	Director/Board Member	61	-

Name	Weight	AuM	Varia. Jan 1.	Investor
GLOBAL X JAPAN MID & SMALL CAP LEADERS ESG ETF - JPY	0.83%	137 M€	+23.03%	-
NOMURA NEXT FUNDS TOPIX-17 IT & SERVICES, OTHERS ETF - JPY	0.1%	18 M€	+15.01%	-
NOMURA NEXT FUNDS NOMURA ENTERPRISE VALUE ALLOCATION INDEX ETF - JPY	0.02%	77 M€	+16.13%	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
BML, INC.	+0.52%	+0.79%	+32.15%	+11.81%	924M
NATERA, INC.	+0.47%	+1.68%	+43.66%	+501.19%	33.41B
SONIC HEALTHCARE LIMITED	+0.26%	-1.03%	-19.95%	-28.21%	7.54B
RADNET, INC.	-2.97%	-4.87%	-0.51%	+274.16%	6.26B
GENEDX HOLDINGS CORP.	-1.81%	-4.81%	+101.55%	+1,156.07%	4.68B
DR. LAL PATHLABS LIMITED	-0.80%	-2.73%	+1.98%	+22.25%	2.84B
GUANGZHOU KINGMED DIAGNOSTICS GROUP CO., LTD.	+0.67%	-1.88%	-11.71%	-58.57%	1.87B
NEOGENOMICS, INC.	-2.42%	-1.94%	-30.98%	+0.55%	1.57B
FLEURY S.A.	+2.65%	-7.98%	+11.98%	-9.89%	1.58B
DIAN DIAGNOSTICS GROUP CO.,LTD.	+1.40%	-3.24%	+21.81%	-44.10%	1.3B
Average	-0.20%	-1.17%	+15.00%	+182.53%	6.2B
Weighted average by Cap.	-0.13%	+0.34%	+28.92%	+379.98%

	2026 *	2027 *
Net sales	148B 952M 819M 767M 715M 1.32B 85.7B 1.44B 8.97B 3.46B 40.48B 3.57B 3.5B	154B 988M 849M 795M 741M 1.37B 88.89B 1.49B 9.3B 3.59B 41.98B 3.71B 3.63B
Net income	6.5B 41.82M 35.95M 33.68M 31.39M 57.98M 3.76B 63.06M 394M 152M 1.78B 157M 154M	7.6B 48.9M 42.04M 39.38M 36.7M 67.79M 4.4B 73.74M 461M 178M 2.08B 184M 180M
Net Debt	-	-